Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,456 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,550 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06568562 | XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer(PRO-XL) | recruiting | Phase 2 | 32 | University of UtahOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07574489 | Whole Versus Partial Gland Boost During Prostate SBRT | not yet recruiting | Phase 2 / Phase 3 | 186 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674121 |
| PROLONG (PRostateOLaparibONcombinationGcc) Study(PROLONG) |
| not yet recruiting |
| — |
| 75 |
| AstraZenecaINDUSTRY |
| 0 |
| Jun 29, 2026 |
| clinicaltrials |
| NCT03436745 | The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04619069 | Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 60 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05940298 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05999968 | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | terminated | Phase 1 | 10 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 26, 2026 | clinicaltrials |
| NCT06641219 | Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen | completed | Phase 1 | 7 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07146113 | Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation(PRIME) | suspended | — | 400 | AstraZenecaINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07591701 | Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson Hospital | recruiting | N/A | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07672119 | A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide | recruiting | — | 3,000 | BayerINDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01251861 | Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 2 | Jun 25, 2026 | clinicaltrials |
| NCT02206334 | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | completed | Phase 1 | 42 | NRG OncologyOTHER | 3 | Jun 25, 2026 | clinicaltrials |
| NCT02217709 | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | completed | Phase 2 | 26 | University of Southern CaliforniaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04530552 | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05079698 | A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer | active not recruiting | Phase 1 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06457919 | A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06599476 | Rectal Spacers in Prostate Cancer Patients Undergoing Radiation Therapy | active not recruiting | N/A | 150 | Advanced Radiation Centers of New YorkOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT03641560 | A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy | completed | Phase 4 | 52 | Astellas Pharma IncINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04746638 | Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m RM26 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06101927 | Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 | completed | Phase 1 | 10 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06359964 | Infective Complications in TP Biopsy Without Antibiotic Prophylaxis | completed | N/A | 1,753 | Chinese University of Hong KongOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07387263 | Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing | recruiting | N/A | 180 | Unity Health TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02095249 | Prostate Hypoxia - TIC | active not recruiting | N/A | 39 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03254420 | Evaluation of Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.(RCMIGI) | active not recruiting | N/A | 74 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04346225 | Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer | suspended | Phase 2 | 75 | Ivan de Kouchkovsky, MDOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04536805 | Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin(REPAIR) | active not recruiting | Phase 1 / Phase 2 | 44 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT04947254 | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06430749 | Targeted Microwave Tissue Coagulation for Prostate Cancer(MicroPro2) | active not recruiting | N/A | 65 | Osamu UkimuraOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06533644 | A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 91 | Syncromune, Inc.INDUSTRY | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07436078 | Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors | recruiting | N/A | 85 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07463833 | Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology | recruiting | N/A | 207 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT00913939 | High-Dose-Rate Brachytherapy | recruiting | N/A | 500 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT01802242 | Tumor TARGET Prostate Cancer | completed | N/A | 85 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02854982 | Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer(EPICAP-QALY) | completed | — | 900 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02918253 | HDR Focal: Feasibility Study | active not recruiting | N/A | 60 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04419402 | Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer(ENZA-p) | active not recruiting | Phase 2 | 162 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04556916 | Early Detection of Prostate Cancer(PROLIPSY) | recruiting | N/A | 320 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04581109 | Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer (EPIDROP)(EPIDROP) | terminated | N/A | 100 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07478536 | Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)(CHAS3) | not yet recruiting | — | 350 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07658573 | AI Multimodal Model for Predicting CRPC Progression Risk(AI-MM_CPRC) | active not recruiting | — | 500 | Guangxi Medical UniversityOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT06625034 | Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer | recruiting | Phase 3 | 108 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) | recruiting | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | recruiting | Phase 1 | 150 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07635238 | A Study of Lower Dose Radiation Therapy for People With Prostate Cancer | recruiting | Phase 2 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 29, 2026source: clinicaltrials